J Korean Diabetes > Volume 20(3); 2019 > Article
The Journal of Korean Diabetes 2019;20(3):149-156.
DOI: https://doi.org/10.4093/jkd.2019.20.3.149    Published online October 2, 2019.
당뇨병 주사제: Glucagon-Like Peptide-1 수용체작용제
,
1
2
3
Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist.
Inkuk Lee, Eun Seok Kang
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. edgo@yuhs.ac
2Severance Hospital Diabetes Center, Seoul, Korea.
3Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.
Abstract
According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease. This recommendation is based on the results of recent cardiovascular outcome trials of this kind of medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established cardiovascular disease, chronic kidney disease, and/or metabolic syndrome.
Key Words: Cardiovascular diseases, Diabetes mellitus, Glucagon-like peptide-1, Kidney diseases, Obesity


Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2021 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer